PDS Biotechnology Corporation (NASDAQ:PDSB)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
PDSB Weekly Chart

Old Forum Content for PDSB

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • woodman: $PDSB @Lou - As I mentioned yesterday, I had a small position. Not anymore. Stops this morning took me out of them. I think what's happening is that too many are irrationally pinning their hopes on a partnership/buyout (I am not) that for some they thought it would happen this week. I see no basis for this other than speculation given the company's money situation. Without a deal, I don't see how it won't have to do a secondary. Institutions don't seem interested. I don't believe it has a legitimate/more realistic catalyst in the near term, so I am out indefintely.
  • woodman: $PDSB - I'm still trying to get to the bottom of what/when are the nearest catalysts for this one (excluding any speculated deal with another company.)
  • Lou: Don't know why I'm still hanging on to a losing position in $PDSB. Will resolve my question today, one way or the other. It's either Sell or Add, and I'm not inclined to Add.
  • woodman: @Lou $PDSB - I agree it has been weak. I have only a small position. I don't think data is until 2Q, so I've stayed mostly on the sidelines with it and kept my biotech $$ elsewhere with those that have or have had earlier catalysts.
  • woodman: #Biotechs I'm focusing on (mostly for at least Q1/H1 2024) (in no particular order): $ARDX (I plan to contnue holding this through full year 2024) $EFTR $XFOR $VKTX $MREO (good buyout potential) $PDSB $INZY $CLRB (mainly for 1/8 data to be presented at JPM Healthcare Conf). Possibly some others as well such as $ORIC (I've lost focus on it and need to reacquaint myself) and $ACAD.
  • MongosPawn: $PDSB Significant percentage pullback this morning (and yesterday) due to news today of resignation and replacement of CFO. Added small on the bounce.
  • woodman: The biotechs I'm in/interested in are perky today and have been perking up for the last 2 or 3 weeks for the most part. Here's an update: $ARDX (new recent high as it seems to want to climb back to the $5-plus next resistance area); $INZY (which @Lou ...
  • Lou: @woodman $ARDX $INZY $VKTX $PDSB - you're the one that deserves the shout-out @woodman. You're the reason I'm long the four above, in varying amounts. $ARDX and $INZY very long and the other two lesser holdings.
  • woodman: @Lou $ARDX $INZY $VKTX $PDSB - well, then, I *really* hope they pan out. :-) It's all good, brutha.
  • MongosPawn: $PDSB $INZY Added small. Long.
  • Lou: @woodman $ARDX $INZY $VKTX $PDSB - thinking about throwing in the towel on $VKTX - stubbornly holding on by fingernails. Off to the gym and will decide before EOD.
  • woodman: @Lou $ARDX $INZY $VKTX $PDSB - Let's see if we can confirm that the obesity data is coming in December. I think that will move the stock.
  • sierramp: @woodman $ARDX $INZY $MREO $VKTX $XFOR $PDSB $EFTR Thanks as always for sharing your research. It is greatly appreciated.
  • woodman: @sierramp $ARDX $INZY $MREO $VKTX $XFOR $PDSB $EFTR - LIttle EFTR having a good day, and breaking out. Tons of volume today. About 8x 50d avg vol.Some very big buys today.
  • Lou: Left for a while and don't detect any significant change other than some executions: STO $EPD puts at 27 and 30 for 1/24; added to $PDSB and $INZY. Fidelity was working for me while I worked out. Probably done until next week. Enjoy Thanksgiving all.
  • woodman: @Lou $EPD $PDSB $INZY - I added to $PDSB too today, also to $EFTR. I have $MREO in my sights for an add, likely tomorrow. Have a nice Thanksgiving.
  • woodman: @Lou $INZY - Nice one. Many of the small biotechs are showing life. $XBI has moved above descending resistance (drawn from 6/12). See, e.g., $PDSB which has been hot. It is trying to hold its latest move up through the 200d (it easily moved up through the descending 50d a week and a half ago). $ORIC and $VKTX are holding their moves through the descending 50d so far. Another interesting one is $MREO which is high consolidation right now.
  • woodman: $PDSB continues to rise. Next hurdle is ~$7.00. If this gets above that, it looks like it could make a run at $10-plus.
  • woodman: $PDSB $VKTX - some lively action in the biotechs.
  • MongosPawn: $PDSB Taking 40 percent off the table here. Earnings next week.
  • woodman: @MongosPawn $PDSB - nice move for you off that double bottom on 10/27. It had recent really good data, as you know, so I wonder what they have coming for earnings/updates call.
  • MongosPawn: @woodman $PDSB Thanks. This batch was from the 10/4 bounce. A 27 percent gain. Very rare for me lately so felt I had to take some off. But am hoping (bad plan) for more next week due to the good data. Although I could change my mind at any minute.
  • woodman: @MongosPawn $PDSB Good luck. I'm away all of Tuesday when they have their call and Wednesday morning as well, so I am passing on holding a position through the call, though I suspect it will be a good one. Catalysts are fleeting, though, and I'd want to be here to manage it if it pops then drops. That isn't a prediction. I have no idea what will happen. I just don't want to be in what could be a volatile position that I am unable to manage.
  • MongosPawn: @woodman $PDSB https://images.app.goo.gl/UEKKRWDyCM9xLtaw5
  • woodman: @MongosPawn $PDSB "Lloyd, I like you; I've always liked you." One of my favorite movies.
  • MongosPawn: @woodman $PDSB In my top 5 for sure. Brilliant, all around (directing, acting, writing, sound, editing, etc.)
  • MongosPawn: $PDSB Premarket bounce. PDS Biotech announces updated survival data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive cancer patients which show 75% survival of ICI nave patients at 36 months
  • woodman: @MongosPawn $PDSB - immediately evaporated, now red. Such is biotech.
  • woodman: @joelsg1 $GPCR - $XFOR $VKTX $PDSB - speaking of biotechs down (actually, crushed over the last whatever), I have $VKTX $XFOR and $PDSB on my potential buy back list for December catalysts. I sold all of them some time ago given their relentless beat ...
  • woodman: @joelsg1 $GPCR - I haven't followed this one. I need to look into it. That's quite a move for phase 1 results in therapeutic area with so many vying for a slice of the huge obesity pie. But my initial reaction is that perhaps we should be re-targetin ...
  • joelsg1: @woodman $GPCR $VKTX $XFOR $INZY $PDSB I wait with bated breath. Followed you into $VKTX for as I recall mixed results, but definitely think a pill is better than the injection, and duct tape across the mouth better yet. Btw, own $AMGN which has its own injectable but lasts at least 3 months per injection vs weekly for the others. Cheers.
  • woodman: @joelsg1 $GPCR $VKTX $XFOR $INZY $PDSB $AMGN - Is Amgen's still phase 1?
  • joelsg1: @woodman $GPCR $VKTX $XFOR $INZY $PDSB $AMGN In Phase 2 now.
  • woodman: @joelsg1 $GPCR $VKTX $XFOR $INZY $PDSB $AMGN - That's good.
  • woodman: $PDSB up about 24% from the bottom bounce. Still holding these trading shares.
  • woodman: $PDSB - this biotech, which recently provided a very good data update on its cancer med candidate and was hammered because no good deed goes unpunished in biotech, is bouncing. For how long, who knows.
  • MongosPawn: @woodman $INZY $PDSB $ARDX Sold a little of my $ARDX as I have a large cushion, sold half of my $INZY and some recent PDSB both for losses. But didn't go large (large for me that is) on any of these except $ARDX which is still up around 55 percent currently. Thanks again for all of your insights.
  • MongosPawn: $PDSB Added small.
  • woodman: @MongosPawn $PDSB - good data over the weekend. But it seems that nothing pushes most biotechs higher these days.
  • woodman: @Onthemark @debeers $ARDX - Thanks but not satisfied with this minor move. I'd like to see a run-up into 10/17. We'll see what happens. So many biotechs, however, have not been running up into catalysts ... and, worse, have not popped on good news. $INZY $PDSB, are recent examples. I don't know what to make of it. Fyi, if we do get a run-up pop in ARDX, I am likely to sell some of my very overweight position. Just as a safety precaution; I continue to believe chances of approval are very high. But there's never any guarantees - neither as to approval (especially with very "curious" FDA decisions not to approve), nor a price pop we all hope for on approval. I'm not trying to discourage you. I'm just letting you know my thoughts. I still fully anticipate holding a quite healthy position through PDUFA.
  • kenb: @woodman $ARDX $INZY $PDSB one of my other spec bio-techs, $IOVA, was on a priority review from the FDA due this quarter and it was notified recently that it's due date was being pushed back to Feb 2024 and the stock cratered. Among the reasons given, was staffing issues at the FDA. Not sure if it will apply to $ADRX as well, but another potential outcome other than approve or deny. We should know in about two weeks. In the meantime, holding a large profitable position. Good luck to all in this.
  • woodman: @kenb $ARDX $INZY $PDSB $IOVA $ADRX - Thanks for that info.
  • kenb: @woodman $ARDX $INZY $PDSB $IOVA $ADRX 04:17 AM EDT, 09/15/2023 (MT Newswires) -- Iovance Biotherapeutics (IOVA) said late Thursday the US Food and Drug Administration needs more time to complete its priority review of the company's lifileucel therapy due to resource constraints. The FDA recently informed Iovance that it had insufficient resources to review the company's response to an information request for the ongoing biologics license application of the product for patients with advanced melanoma. The regulator extended the new target action date to Feb. 24 and agreed to work closely with the company to accelerate the remaining review for a potentially earlier approval date. Iovance said the FDA reiterated that there are no major review issues and no plans to hold an advisory committee meeting.
  • woodman: @kenb $ARDX $INZY $PDSB $IOVA $ADRX Re IOVA, I have no position but it seems like yet another irrational drop of the stock price for a small biotech (if viewed in terms of this delay not meaning anything substantively - the story hasn't changed). I g ...
  • woodman: $INZY $PDSB - I also sold the last of my PDSB today, though I didn't have much left to sell. I think it has data to report tomorrow or later this week, and my guess is that it will be good, but this weekend's was good and the stock dove anyway. Biotech is a graveyard right now as it's been for some time. I do still have my $ARDX position and one other - a lottery ticket I've been holding for a long time and will keep holding - but I'm not in any others right now except for placeholders or very small positions. Just an FYI.
  • woodman: @MongosPawn $INZY $ORIC - I pulled the plug on ORIC in my two accounts that had it on 8/28 and 9/14, respectively. My decisions were a combo of the chart and my desire for things I wanted more as I consolidated my biotech holdings. I'm down to very few biotechs, though I have some on the horizon that I used to own (i.e. want to buy back). My primary biotech holdings currently are $ARDX (large position), $INZY and $NWBiOturd ($NWBO - a lottery ticket stock that I've held for some time, which I seem recently to have caught nicely in the $0.40s & $0.50s to add to my shares that I bought higher). $PDSB remains interesting and has a bunch of catalysts coming this week and next! I am looking possibly to buy back some of those shares. I also will buy back $XFOR for catalysts in December.
  • woodman: $INZY (September) and $PDSB (possibly September but I think more likely early October) have multiple data readouts. I own both (larger position in INZY than PDSB). I'd like to add to them, but will have to sell other things I don't want to sell. Still working on that plan....
  • MongosPawn: @woodman $INZY $PDSB Added some $PDSB today.
  • woodman: @MongosPawn $INZY $PDSB - Plus my bioturd $NWBO is showing some life. It will be submitting for UK approval of DCVax-L (for glioblastoma) in about 30 days.
  • Lou: @woodman $PDSB - ditto what I said about ARDX.
  • woodman: $PDSB has been frisky. Catalysts - various data - due Q3 from what I have seen.
  • woodman: $ARDX $XFOR $INZY $ORIC $PDSB - My biotechs are working well today but, alas, they are all still in a range, though ORIC may be poised to move up out of its range (we'll see).
  • woodman: $PDSB - I'm rebuilding a position in this one. Lots of important catalysts coming in October. Deep pipeline. It has some collaborations with $MRK (combo with Merck's Keytruda which is the SOC in those areas currently, but Merck needs to extend its patent so is in a lot of trials with other companies' cancer drug candidates). It's also working with with Mayo Clinic, MD Anderson and NIH/NCI. See pipeline here: https://www.pdsbiotech.com/index.php/pipeline/pipeline-oncology Currently trading at $6.32 (up from $4.62 Friday last week). Price targets: Cantor $25; HCW $21; Oppy $24; CG Capital $18. For some good info, see if you can get CG Capital's latest report from August. Google "CGCapital PDSB" then hit the images tab at top of your browser (if using Chrome, this works). Not sure if it will bring up this most recent report (August); it may only give you an earlier one.
  • sierramp: @woodman $PDSB $MRK Thank you for sharing your research. Impressive collaborations, partner funded trials and PTs. The number of funds with ownership has been climbing, now at 82. I took a starter.
  • woodman: @sierramp $PDSB $MRK - You're welcome, and good luck!
  • jwstich: @woodman $PDSB $MRK. I took a very small pilot position. Thanks for your hard work and generosity.
  • woodman: @wijimmy $NANC $KRUZ $QQQ $EFTR - I don't have any more intel on EFTR. I need to look into it. My position remains small. It has two catalysts due this half of the year, but I don't know when. Some others have been of greater immediate interest to me with coming catalysts: $XFOR (I'm very interested - and have a healthy position - in this one with its much anticipated CN data coming this month or next, I'm guessing) and $INZY (one on Wednesday then next Q). $ORIC seems to be making a run into catalysts this half of the year, but I don't have a specific month even. Others of interest include these struggling ones: $TERN (catalysts this Q and another this H), $VKTX (two catalysts this H). $PDSB (one this H).
  • Lou: @woodman -$PDSB is finally showing life.
  • woodman: @Lou $PDSB - I have only a placeholder position currently. I had started buying it back but it fell through levels and I didn't like it, so I sold. I'd still like to buy it back for catalysts this half of the year, but I have to thread some needles w ...
  • woodman: @Lou $PDSB - for got $ORIC, another one I have and want to build on for catalysts this half. Probably won't be able to build them all to the levels I'd like.
  • MongosPawn: $PDSB Stopped out.
  • MongosPawn: $PDSB Stater taken here. Stop just below the March low.
  • woodman: ...
    Additionally, TERN is one of the bios I'm holding over their additions into the Russell 3000 on Fri 6/23 amc (for trading in the index on Mon 6/26). Funds will have to buy it. In addition to TERN, I have several other biotechs that will be added to ...
  • woodman: $PDSB - I *think* this has bottomed in terms of its post-ASCO pullback. That said, it's now hitting the overhead moving averages (virtually all of them clustered in one spot), so turbulence is to be expected. Hopefully, it won't reverse back down and will just, at worst, continue to consolidate a bit. But, I did buy some back at 6.22.
  • Lou: @woodman $PDSB - still holding from below. Nice boring holding.
  • Margi1983: @woodman $PDSB But the did not prosecute Elon for " financing secured" when the tweeted about taking $TSLA private. And what about the CEO of SVB??
  • marklesparkle: @woodman $PDSB I got a little yesterday Woodman we'll see. I have ownd it before thanks to you so I'm with you again man
  • woodman: @Margi1983 $PDSB $TSLA - True. And many other examples. SEC is very weak. As if non-existent.
  • woodman: $PDSB $TSLA - and yet it's suing $COIN. I have no idea what goes on over there.
  • woodman: @marklesparkle $PDSB -It could be dead money for a bit, and some who bought late will think they are bagholders now if they haven't already sold. But there are more catalysts coming this Q and next Q, and next year. The data presented at ASCO are very good. It's getting praise in the right circles. Phsyicians like what they see. The biotech analysts have defended and reiterated their PTs (Oppy $24; Cantor $25; HC Wainwright $21). Yesterday's noise should will dissipate fairly quickly. I think more than anything is that there often are pullbacks after ASCO. This one is compounded by misinformation that the person delivering that misinfo addmitted and tried to remediate. But that's just one component which is added to the general post-ASCO malaise. I added to my shares yesterday. We'll see what happens in time.
  • woodman: $PDSB - I'm still a fan, but stops have been hit for me. So, I will be looking for a place to reenter. Today is Day 3 so it may come back soon. There's just so much noise pushing this one around. Just wanted to be transparent with what I'm doing.
  • woodman: $PDSB - add CG Capital to the list of analyst shops reiterating their prior PTs for this one. It just reiterated its $18 PT and a nice report saying the data remains encouraging.
  • marklesparkle: @woodman $PDSB Thanks man yeah I got shaken out but im going back . why dont you mention when you're jumping on board again
  • gtr89: @woodman $PDSB never a dull moment in the biotech sector. High risk and high reward. Since I my $PDSB is a spec size position, I’m going to hang on and see what develops. Always appreciate your posts
  • woodman: @marklesparkle $PDSB - I did add some back later in the day, but I'm still mostly out. Unfortunately, I'll be away until Friday mid-day and not able to do anything. I have a bad feeling it will bounce back and I'll have missed it as a stopped out Bull. Ugh. Bad timing.
  • Onthemark: $PDSB trading halted
  • Henry: @eresnick10 $PDSB from what I can gather on Twitter, their abstract revealed 4 deaths in a study group.
  • woodman: @Henry $PDSB - Not quite the story.
  • woodman: @Henry $PDSB - Today has to do with poster's meaning of and reasons for "confirmed" and "unconfirmed" response rates. among other things.
  • woodman: @Henry $PDSB - ... and to add fuel to the fire, there's confusion over a purported potential new competitor in the TA, but $PDSB and the other company are dealing with two different patient populations. But people are just going haywire anyway.
  • woodman: $PDSB - Tomorrow will be an important call. Hopefully, it will resolve the confusion caused by some commentators today. Fwiw, Oppenheimer came out with a note earlier this afternoon explaining that today's rollercoaster was due to a poster put on P ...
  • woodman: $PDSB - if in, or otherwise interested in, this one and you've been following today's crazy ASCO events, the reporter who lit the fuse and exploded the bomb on Twitter which, at least in part caused today's crazy drop, has now apologized for not know ...
  • gtr89: @woodman $PDSB I have a day job, so I was late to the drama today since I didn’t first check my positions until later in the day. I made a small add and hopefully tomorrow I won’t regret not selling instead lol. As always, thanks for the updates
  • woodman: @gtr89 $PDSB - And this tweet about an hour and a half ago is downright embarrassing for a "reporter," if not inculpatory in any coming SEC investigation or lawsuit against him: Jacob Plieth @JacobPlieth I of course shouldn't have implied that $PDSB was "pumping" in 25 May PR, so I apologise for that. Rather, the whole chain of events has been rather confusing.
  • gtr89: @woodman $PDSB although $PDSB is a spec stock, it’s insane how a tweet from a guy like this can cause such a high volume sell off. If he was involved in manipulation, I hope the SEC prosecutes him and any others involved, but given the poor LT track record of the SEC, I’m not confident that there will be accountability. It’s a good lesson to not go too big into any one spec stock
  • woodman: @gtr89 $PDSB - I agree. And I wonder if something else was adding to it. I do know that, separately today, there was confusion about a supposed competitor's drug data for a purported competing drug, but I also think that info was erroneous because the two companies trials/targets involve different populations. I think that may have affected things today. So it was an odd day for sure, with a lot of noise from different directions, today.
  • woodman: $PDSB @gtr89, et al. - Update: Oppenheimer earlier in the day and Cantor a few hours ago have come out to say the reporter - Jacob Plieth (a frequent biotech reporter) - had no idea what he was talking about. Cantor this evening reiterated its $25 PT and Plieth confused progressive disease data with confirmed and unconfirmed responses. So, the sell-off was unwarranted (though again weird that one idiot reporter could set off such events). Nonetheless, the analysts appear all to be defending PDSB saying the fundamental story remains unchanged. Good luck to us tomorrow.
  • woodman: $PDSB - ASCO run continues.
  • debeers: @woodman $PDSB -You are the biotech king!
  • woodman: $PDSB - I'm still in this and have been adding (both before and after the 5/25 pre-ASCO data announcement for one of its many cancer trials). It will be presenting a fuller picture of the recent data at ASCO in the afternoon on Mon. 6/5 followed by a ...
  • gtr89: @woodman $PDSB $MRK thanks for the $PDSB update. Nice move on volume today. I still have my full position and intend to keep holding, but it is tempting to take some off
  • woodman: $PDSB solid (pre-ASCO) mover all day today. I last added yesterday at 8.64 in the flag. Wish I had been around this morning to add more on the early part of the move. ASCO presentation is June 5. (See earlier post today.)
  • woodman: @gtr89 $PDSB $MRK - I'm sticking with mine through ASCO and following presentation/conference call. Then I'll decide what to do in terms of taking some off to use the $$ elsewhere. There are a number of biotechs I'd like to add to, but I have to sell things to do that. It's a lot of whack-a-mole and threading needles to try to rotate money around these without missing a catalyst run in one while taking advantage of dips in others. And PDSB has so much going on, it may be hard to sell without missing the next catalyst run.
  • woodman: $PDSB - sorry, added at 8.64 and 8.55 yesterday.
  • gtr89: @woodman $PDSB I hold a small position in this stock, so thanks for covering this stock. You gave readers a heads up about upcoming news the other day. It’s up 25%%2B this morning beating $NVDA’s much talked about gain yesterday lol.
  • gtr89: $PDSB up 28%%2B this morning on results. See @woodman post below
  • Henry: @gtr89 $PDSB I'm sure I will have a Homer Simpson moment when you tell me what %2B means.
  • Docoof: @Henry $PDSB I think it’s the first use of the plus symbol in the sentence. So if I write “Up 2 plus” but use the “plus” symbol it looks like this: Up 2%2B.
  • gtr89: @Docoof $PDSB Apparently one can’t use the plus sign after a percentage sign. News to me. Doesn’t change the facts in the post though.
  • Docoof: @Henry $PDSB in other words, just a glitch that hasn’t been worked out yet. And in the above sentence, I did use the plus symbol on the keyboard, but what you see above is how it looks when it was posted.
Visit the Trading Forum to join in the discussion.
Stock Price $2.90
Change 6.62%
Volume 1,127,650

Edge Therapeutics Inc is a United States based company engaged in the research and development of medical therapies. Its products address serious unmet neurological disorders.

Request Video of PDSB
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!